X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Administration’s Special 301 Report highlights deteriorating global environment for biopharmaceutical innovation

By Jay Taylor  |    May 23, 2017
In the latest publication of its annual Special 301 Report, the Office of the U.S. Trade Representative (USTR) brings renewed attention to intellectual property (IP) and market access challenges...   Read More

Compulsory licensing: A misused and abused international trade law

By Jay Taylor  |    May 16, 2017
To maintain our position as the world’s top biopharmaceutical innovator, the U.S. biopharmaceutical industry needs predictable and reliable intellectual property protections. Compulsory licensing...   Read More

Government-imposed price controls threaten innovation and access

By Jay Taylor  |    May 9, 2017
It’s no coincidence that America leads the world in the discovery and development of new lifesaving medicines. U.S. biopharmaceutical innovators invest $60 billion in R&D annually – more than any...   Read More

ICYMI: Ubl weighs in on how fair trade protects US biopharmaceutical innovation

By Mark Grayson  |    May 5, 2017
America’s biopharmaceutical leadership is a result of a robust medical innovation ecosystem driven by several factors: a free-market economy that rewards innovation, strong intellectual property...   Read More

Illegal trade barriers discriminate against U.S. innovators

By Jay Taylor  |    May 2, 2017
America has long led the world in medical innovation – which brings breakthrough, lifesaving medicines to people around the world, and supplies 4.5 million biopharmaceutical jobs to American...   Read More

Australia is making it harder to protect inventions. That’s bad for American businesses and jobs.

By Jay Taylor  |    April 25, 2017
Bringing a single new medicine to market requires substantial resources over many years. To ensure continued investment in the development of tomorrow’s breakthrough treatments and cures,...   Read More

Trading fair means upholding the law: A focus on patents

By Jay Taylor  |    April 18, 2017
Patents are the linchpin of innovation. In the United States and other countries around the world, they provide temporary protection for new inventions. A fair, stable and predictable patent...   Read More

Enforcing unmet trade obligations protects U.S. innovation

By Jay Taylor  |    April 11, 2017
The United States leads the world in medical innovation, helping patients across the globe access the latest life-saving treatments and cures. Trade agreements with other nations serve as the...   Read More

NAFTA tribunal fails to rule on Canada’s patent utility doctrine

By Mark Grayson  |    April 4, 2017
While Canada may have prevailed in the recent North American Free Trade Agreement (NAFTA) tribunal case against Eli Lilly, the promise utility doctrine continues to harm their economy. And,...   Read More

PhRMA urges USTR to protect American innovators abroad

By Mark Grayson  |    February 10, 2017
Yesterday, PhRMA submitted comments for the 2017 Special 301 Report the Office of the U.S. Trade Representative (USTR) will publish in April. The comments highlight serious intellectual property...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates